Sanofi and GSK have initiated a Phase I/II trial of their Covid-19 vaccine candidate. Credit: PIRO from Pixabay.

Sanofi and GlaxoSmithKline (GSK) have signed a deal with the Government of Canada to supply up to 72 million doses of adjuvanted Covid-19 vaccine candidate from next year.

The vaccine candidate derives from Sanofi’s recombinant protein-based technology, as well as GSK’s pandemic adjuvant technology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The companies launched a Phase I / II clinical trial on 3 September, with initial data expected December. These results could support a Phase III trial.

If researchers obtain positive trial data, the companies will apply for regulatory approval in the first half of next year.

Sanofi and GSK are working to step-up manufacture of the antigen and adjuvant to produce up to one million doses annually worldwide.

Sanofi Pasteur executive vice-president and global head Thomas Triomphe said: “To address a global health crisis of this magnitude, it takes partnerships and we are grateful to Canada for their collaboration, and to GSK for partnering with us to develop a safe and effective vaccine.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GSK said it does not expect to make a profit from Covid-19 vaccines during the pandemic. The company will invest any short-term income in research on coronavirus.

In a separate development, the Canadian government further increased its confirmed order commitment to 20 million doses of Moderna’s Covid-19 vaccine candidate, mRNA-1273.

Earlier this month, Sanofi and GSK signed a deal with the European Commission to provide up to 300 million doses of their Covid-19 vaccine candidate.

In July, Sanofi and GSK partnered with the US Government to supply up to 100 million doses of the potential vaccine. The government committed to provide up to $2.1bn to support the project.

Furthermore, the companies will supply up to 60 million doses to the UK Government.

Sanofi and GSK plan to deliver a portion of the total available global supply capacity to the COVAX initiative.